Emofilia Emocizumab

Understanding hemophilia

Complete Anatomy

Guidelines for Emicizumab and aPCC Treatment of Hemophilia

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated...

National Bleeding Disorders Foundation

Optimizing Emicizumab Therapy in Hemophilia Treatment

Specialty Pharmacy Times

Dosing and Safety for Emicizumab plus aPCC

Emicizumab’s Impact on the Hemophilia Treatment Landscape

Specialty Pharmacy Times

Emicizumab In Obese Versus Non-obese Adults With Hemophilia A

Hemophilia Federation of America

HAVEN 7: emicizumab prophylaxis for the treatment of infants with severe hemophilia A

VJHemOnc – Video Journal of Hematology & HemOnc

HAVEN 6: emicizumab prophylaxis in non-severe hemophilia A without FVIII inhibitors

VJHemOnc – Video Journal of Hematology & HemOnc

Emicizumab for hemophilia A: interim analysis of the real-world EMIIL study

VJHemOnc – Video Journal of Hematology & HemOnc

Efficacy, Approval, and Personal Experience with Emicizumab

Appropriate Selection of Emicizumab for Hemophilia

Specialty Pharmacy Times

Monitoring the Coagulation Status of People with Hemophilia Receiving Emicizumab

National Bleeding Disorders Foundation

The impact of emicizumab prophylaxis on caregivers' burden for patients with hemophilia A

VJHemOnc – Video Journal of Hematology & HemOnc

Emicizumab Prophylaxis and Management of Breakthrough Bleeding Events

National Bleeding Disorders Foundation

Subcutaneous Prophylaxis with Concizumab in Hemophilia A and Hemophilia AB with inhibitors

ISTH

Where could hemophilia treatment go next?

A potential novel hemophilia treatment: an in vitro study of eptacog beta and emicizumab

VJHemOnc – Video Journal of Hematology & HemOnc

Immune tolerance induction in the era of emicizumab

National Bleeding Disorders Foundation

HEMLIBRA® (emicizumab-kxwh) Mechanism of Action for Haemophilia A